In the landscape of modern medicine, we have mapped the human genome, developed mRNA vaccines in record time, and pioneered robotic surgeries that can reach the most delicate structures of the human body. Yet, there remains a persistent, festering, and largely overlooked crisis that affects nearly one in three people living with diabetes over their lifetime.
The diabetic foot ulcer (DFU) is a condition that carries a five-year mortality rate rivaling many common cancers and serves as the precursor to more than 85% of all diabetes-related amputations. Despite its devastating impact on patients and the healthcare system, the field has seen almost no transformative innovation in nearly 30 years. It is a condition that has been seen by all, but truly owned by few, and it is long overdue for a reckoning.
The Fragmented Frontline: A Disease Without a Home
Wound medicine is perhaps one of the most inherently multidisciplinary fields in all of healthcare. However, this diversity of care is often the patient’s greatest obstacle. To properly manage a single diabetic foot ulcer, a patient may require the synchronized input of primary care physicians, podiatrists, vascular surgeons, infectious disease specialists, wound care nurses, nurse practitioners, physical therapists, and plastic and reconstructive surgeons.
On any given day, a single patient may be bounced between half a dozen different specialists, each operating under their own set of guidelines. This fragmentation is exacerbated by a significant institutional gap: wound medicine is not a board-certified specialty under the American Board of Medical Specialties. There is no singular governing body with the authority to unify clinical protocols, standardize training, or act as a powerful, collective advocate for patients.
For the patient, this is far more than an administrative burden. It creates a vacuum of accountability. Chronic wounds demand clinicians who are willing to act outside of their defined roles, not because the system incentivizes it, but because the clinical reality necessitates it. Without this "extra-mile" care, the wound simply does not heal.
The Biology of Stasis: When the Body Forgets How to Mend
To understand why the DFU has remained so intractable, one must look at the physiological "perfect storm" that creates it. Diabetic foot ulcers do not appear in a vacuum; they are the downstream consequence of decades of systemic damage.
Peripheral neuropathy—the loss of sensation in the feet—is the primary catalyst. Patients literally cannot feel the pressure points developing as they walk. Simultaneously, long-standing diabetes causes structural changes in the foot’s anatomy, shifting weight distribution and accelerating the breakdown of skin and soft tissue. Layered on top of this is peripheral arterial disease, present in approximately 50% of DFU patients, which restricts blood flow and starves the extremities of the oxygen and nutrients required for repair.
Once an ulcer forms, these factors conspire to prevent healing. Because the patient cannot feel the wound, they continue to place weight on it, traumatizing the tissue further. The wound becomes trapped in a chronic inflammatory state. Bacteria colonize the wound bed, forming protective biofilms that render conventional topical treatments useless. Surrounding skin cells become senescent—functionally "exhausted"—and the wound effectively loses its biological memory of how to heal.
Chronology of a Cascade: From Ulcer to Amputation
The clinical trajectory of an untreated DFU is a well-documented and harrowing sequence. It begins as a localized breach in the skin, but without rapid intervention, it quickly escalates. Infection, which complicates approximately 60% of DFUs, becomes the primary driver of emergency department visits and hospitalizations.
As the infection deepens, it can lead to osteomyelitis—a bone infection that occurs in roughly 15% of cases. When osteomyelitis is present, the amputation rate climbs sharply, approaching 90% in cases of severe infection. Even after surgical debridement—the removal of dead and infected tissue—the recovery is fragile. Up to 25% of patients show persistent infection 10 to 20 days post-procedure, and 10% to 45% of patients require hospital readmission within one year.
The human and economic costs are staggering. The lifetime incidence of lower-extremity amputation among those with a DFU is approximately 20%. When viewed through the lens of policy, the data is damning: because 85% of amputations are preceded by an ulcer, the vast majority of these life-altering surgeries are theoretically preventable.
The mortality associated with these amputations is sobering. Following a major lower-extremity amputation, the five-year mortality rate is estimated at 50% to 70%. Despite our technological advances, the incidence of DFUs is rising in tandem with the global diabetes epidemic and an aging population. In some regions, amputation rates have surged by as much as 50% over the last several years, with a particularly concerning rise among younger patients and racial and ethnic minority populations.
The Innovation Stagnation: A Three-Decade Gap
Given the sheer scale of the morbidity and mortality associated with chronic wounds, one would expect the wound care market to have seen the kind of revolutionary therapeutic shifts that have transformed oncology or immunology. It has not.
The last biologic therapy that received Biologics License Application (BLA) approval from the FDA for a common chronic wound indication was in 1997. Since then, the market has been saturated with advanced dressings and skin substitutes derived from synthetic matrices, animal tissue, or donated human tissue. While there has been a genuine explosion in the number of branded products, the underlying science has remained largely stagnant. We have seen incremental improvements in convenience and ease of use, but we have failed to deliver therapies that address the root biological cause of wound chronicity.
Implications for the Future: Borrowing from Oncology
If the current paradigm is failing, where does the path forward lie? The oncology field provides a compelling blueprint. Over the past decade, cancer treatment has shifted away from generalized toxic therapies toward precision, autologous, and cell-based approaches. By utilizing the patient’s own biology, clinicians have been able to treat once-intractable malignancies.
The field of regenerative medicine is now beginning to apply this logic to the diabetic foot. A DFU is, at its most fundamental level, a wound that lacks the patient’s own functional skin cells. While traditional reconstructive surgery has long relied on autologous tissue (skin grafts), these methods struggle in the DFU patient because the very factors that caused the ulcer—poor blood supply, lack of sensation, and systemic inflammation—often cause the graft to fail.
The next frontier involves a variety of investigational regenerative approaches, including:
- Autologous cellular therapies: Harvesting and expanding a patient’s own healthy cells to "re-seed" the wound bed.
- Exosome-based approaches: Utilizing the signaling molecules produced by healthy cells to "instruct" the chronic wound to re-enter the healing cycle.
- Gene-based strategies: Addressing the underlying genetic expression that keeps the wound in an inflammatory state.
Conclusion: Giving Patients Their Lives Back
For a patient living with a diabetic foot ulcer, "wound closure" is not merely a clinical milestone; it is a life-changing event. It represents the end of a cycle of clinic visits, hospitalizations, home nursing, and the looming, constant threat of amputation. It means regaining mobility, independence, and the dignity that is so often stripped away by chronic disease.
We know that closing ulcers quickly is the most effective intervention point to prevent the downstream cascade of amputation and premature death. The challenge ahead is to stop focusing on the "band-aid" solutions of the last thirty years and begin investing in the regenerative biological solutions of the next.
The diabetic foot ulcer has been ignored by the broader innovation ecosystem for too long. By moving toward specialized, multidisciplinary care models and embracing the potential of regenerative medicine, we can finally stop this cycle. It is time to treat the diabetic foot ulcer not as a minor complication of diabetes, but as the urgent, systemic crisis that it is.
About the Author
Dr. Ned Swanson is the President and Chief Medical Officer at PolarityBio, where he drives the strategic vision and clinical development of innovative therapeutic solutions. Dr. Swanson brings a unique interdisciplinary perspective to regenerative medicine, holding an MD from Harvard Medical School and a degree in Bioengineering from the University of Pennsylvania. He further refined his clinical acumen and surgical skills during his Plastic Surgery residency at Johns Hopkins.
